• image

    the Phase 3 trial DIAGNODE-3

    and other ongoing trials

  • image

    Developing precision therapies

    for type 1 diabetes

  • image

    Intralymphatic immunotherapy

    with Diamyd®

Company Presentation

 March 28, 2024

The recent granting of Fast Track designation by the U.S. FDA for our flagship product Diamyd® is a milestone that both accelerates the path to bringing our innovative treatment to patients with Type 1 Diabetes and validates the urgent need for our therapy.

image Ulf Hannelius
President and CEO, Diamyd Medical AB
CEO Comments, Quarterly Report 2 23/24


 Dates for financial information and other events
June 14, 2024
Decoding the Future
June 21 − June 24, 2024
ADA 84th Scientific Sessions
June 26, 2024
Quarterly Report III
Quarterly Report 3 2023/2024
September 9 − September 13, 2024
EASD 2024
October 9, 2024
Year-End Report
Year-End Report 2023/2024
October 16 − October 19, 2024
ISPAD 2024
November 4 − November 8, 2024
IDS 2024

The Story of Diamyd Medical

The company founder Anders Essen-Möller reveals the story behind the company's founding and his mission to stop type 1 diabetes in its tracks. The film also features board member Karin Hehenberger, shedding light on the patient’s perspective, and board member Dr. Mark Atkinson speaking of the importance of the enzyme GAD in type 1 diabetes.

“ If it was not for the hundreds of clinical sites and their personnel, investigators, patients, investors, not to mention the fantastic entrepreneurial, yet diligent, Diamyd team - this current transformational precision therapy for autoimmune diabetes based on genetics, should probably still remain undiscovered.
How can I thank you all ? "

- Anders Essen-Möller, Chairman of the Board
A new facility for manufacturing of biological products is being set up in Umeå, the Capital of Västerbotten County in Sweden. The primary purpose is the manufacture of recombinant GAD65, the active pharmaceutical ingredient in the investigational medicine Diamyd®, an antigen-specific immunotherapy currently in late-stage clinical development.

Diamyd Medical has chosen Cytiva’s FlexFactory, a configurable single-use bioprocess platform for the manufacturing process that is based on a baculovirus-insect cell expression system.
Read More


Diamyd Medical develops therapies for type 1 diabetes
The share is listed on Nasdaq First North Growth Market (ticker: DMYD B)

Read More

Order GAD for preclinical research